SNTI: Senti Biosciences, Inc. Stock

by  •  • Comments Off on SNTI: Senti Biosciences, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 97.00
Enterprise Value ($M) 73.83
Book Value ($M) 50.76
Book Value / Share 1.95
Price / Book 1.91
NCAV ($M) 11.88
NCAV / Share 0.46
Price / NCAV 8.17

Profitability (mra)
Return on Invested Capital (ROIC) -0.63
Return on Assets (ROA) -0.52
Return on Equity (ROE) -0.94

Liquidity (mrq)
Quick Ratio 4.49
Current Ratio 4.49

Balance Sheet (mrq) ($M)
Current Assets 58.96
Assets 97.84
Liabilities 47.09
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -54.28
Net Income -52.79

Cash Flow Statement (mra) ($M)
Cash From Operations -41.40
Cash from Investing 0.03
Cash from Financing 53.73

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-17 13D/A Celadon Partners SPV 24 37.60 0.00
03-10 13D/A New Enterprise Associates 15, L.P. 14.50 753.02
02-14 13G Armistice Capital, Llc 9.99
02-14 13G Nantahala Capital Management, LLC 9.99
02-14 13G Nantahala Capital Partners Limited Partnership 5.91

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PUR
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PUR
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUAN
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRAN

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 2,304 8,029 28.70
2025-04-16 8,142 18,973 42.91
2025-04-15 3,040 15,880 19.14
2025-04-14 7,203 36,727 19.61

(click for more detail)

Similar Companies
SNGX – Soligenix, Inc. SNPX – Synaptogenix, Inc.
SNSE – Sensei Biotherapeutics, Inc. SNYR – Synergy CHC Corp.
SONN – Sonnet BioTherapeutics Holdings, Inc.


Financial data and stock pages provided by
Fintel.io